|
Development of New Approach Methodologies to Reduce Animal Use in Toxicity Testing -SBIR/STTR Town Hall Meeting
|
Meeting/ Workshop
|
FDA
|
NIEHS
|
This webinar-based town hall meeting was presented to facilitate improved communication between New Approach Methodologies (NAMs) method developers, including small business (SBIR/STTR) applicants, developing assays to reduce animal use in toxicity testing, and end-users and regulatory agency staff, providing an opportunity for the assay developers to hear from ICCVAM, agency and industry stakeholders on the desired characteristics and requirements for NAM to meet testing requirements.
|
|
Diabetes Mellitus Interagency Coordinating Committee (DMICC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OASH
|
NIDDK, NHGRI
|
The DMICC facilitates cooperation, communication, and collaboration on diabetes among the participating government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate.
|
|
Diabetes Prevention Program Outcomes Study (DPP/DPPOS)
|
Research Initiative
|
CDC
|
NIDDK, NCI, NHLBI, NIA
|
The Diabetes Prevention Program (DPP) showed that lifestyle change or the drug metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long-term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP.
|
|
Diabetic Eye Disease Information Dissemination
|
Public Education Campaign
|
CDC
|
NEI
|
The Centers for Disease Control and Prevention (CDC's) National Diabetes Education Program is part of the National Eye Health Education Program Partnership. The National Eye Institute (NEI) continues to collaborate with CDC and other stakeholders to share information about diabetic eye disease with various communities.
|
|
Diabetic Retinopathy Clinical Research Network
|
Research Initiative
|
OS
|
NEI, NIDDK
|
The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the National Eye Institute (NEI), and co-funded by the Office of the Secretary (OS), through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with the Special Funding Program for Type 1 Diabetes Research.
|
|
Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population
|
Research Initiative
|
CMS
|
CC
|
Centers for Medicare and Medicaid Services (CMS) and the National Institutes of Health (NIH) Clinical Center (CC) Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research, the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to the NIH Clinical Center, which will perform analyses that are agreed to by both parties.
|
|
Diagnostics and Disease Management Tools for Use in Underserved Populations: An NHLBI Research & Implementation Workshop
|
Meeting/ Workshop
|
AHRQ, CMS, CDC, FDA, OASH, HRSA, IHS
|
NHLBI, NCATS, NIMHD, NIBIB
|
On April 14-15, 2021, the NHLBI convened a virtual workshop aimed at using technology to improve heart, lung, blood, and sleep health in historically underserved, low-resource, and remote communities. The goal was to identify more accessible and feasible technological solutions for disease diagnosis and management in these groups, highlight the ones that could have the greatest impact, and determine the ones best suited for further research. During the two-day event, approximately 1,800 participants came together to discuss sustainable and affordable technology solutions, effective community-based strategies, aand innovative models for disease management and diagnosis in underserved populations. Participants included academic researchers, implementation scientists, technology and medical device experts, and community and federal health leaders.
|
|
Diet-induced Hypomethylation in Preneoplastic Liver/Genetics ; Epigenetics of Susceptibility to Non-Alcoholic Fatty Liver Disease
|
Research Initiative
|
FDA
|
NCI
|
The Food and Drug Administration (FDA), the National Center for Toxicological Research, and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies.
|
|
Digestive Diseases Interagency Coordinating Committee (DDICC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA
|
NIDDK, NCI, NIBIB
|
The Digestive Diseases Interagency Coordinating Committee is charged with facilitating cooperation and collaboration in research efforts in digestive diseases among NIH Institutes and other relevant Federal health agencies to provide a structure for coordinated efforts to combat digestive diseases. The Committee also prepares reports on the status of digestive disease research funding as well as needs for future research in specific areas of digestive diseases. The Committee meets to encourage exchange of information among member organizations and develop common initiatives.
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
CC
|
This project is a collaboration between the National Institutes of Health (NIH )Clinical Center and the Food and Drug Administration (FDA)that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis, and therapy monitoring of marrow disorders.
|